2Assist. Prof., MD., Sankar Foundation Eye Institute, Visakhapatnam, Andhra Pradesh, India, Department of Retina Vitreous, Visakhapatnam, India
3Ophthalmologist, MD., Sardar Patel Post graduate Institute of dental and medical sciences, Lucknow, Uttar Pradesh, India, Department of oral and maxillofacial pathology and oral microbiology, Lucknow, India DOI : 10.37845/ret.vit.2021.30.11 Purpose: To estimate the utilization of bevacizumab and to monitor disease in patients with the branch or central retinal vein occlusion (BRVO/ CRVO) and diabetic macular edema (DME) in clinical practice.
Material and methods: This hospital-based prospective study comprised 102 patients with macular edema with DME and RVO. Intravitreal injection of 1.25 mg/0.05ml Bevacizumab was administered following standard surgical protocol. All eyes were bi-microscopically examined preoperatively and post-operatively.
Results: As per the optical coherence tomography (OCT) results of Central Foveal Thickness (CFT), the amount of CFT in DME patients reduced to 278.20 ± 68.91(initial: 511.02 ± 131.92); in BRVO patients, it was reduced to 219.04 ± 53.61 (initial: 425.83± 151.68); and in CRVO patients, it was reduced to 292.14 ± 46.99 (initial: 598.71 ± 87.27) after the injection at the end of 1 year. There was signifi cant difference observed between the initial and end of follow-up CFT (p<0.0001).
Conclusion: The study showed that the intravitreal Bevacizumab is an effective and way to treat macular edema related to diabetic eye disease and retinal vein occlusion.
Keywords : Branch retinal vein occlusion, Central retinal vein occlusion, Diabetic macular edema, Bevacizumab, Optical coherence tomography